Jury's members
President : Pr Sir Michael RAWLINS
Vice-President : Pr Parveen KUMAR
Secretary general :Jane GARMON-JONES
Members :
• Dr Jane ADAM, chairman of the Technology Appraisal committees of the National Institute for Health and Clinical Excellence.
• Dame Carol BLACK, National Director for Health and Work, Chairman of Nuffield Trust, President of the British Lung Foundation and Pro-Chancellor at the University of Bristol.
• Pr Sir Gordon DUFF, Florey Professor of Molecular medicine, University of Sheffield, Honorary Consultant Physisian, Sheffied Teaching Hospital NHS Foundation Trust.
• Pr Deirdre KELLY, Commissioner on the Care Quality Commission, President of the European Society and Paediatric Gastroenterology.
• Pr Parveen KUMAR, Professor of Clinical Medical Education, Reader in Gastroenterology, Honorary Consultant Physisian and Gastroentelogist, London, Associate Director for International Education, Royal College of Physicians.
• Dr Mark PORTER, General Practitioner and Media Doctor.
• Sir Michael RAWLINS, Chairman of the National Institute of Health and Clinical Excellence (NICE), Honorary Professor, London Shool of Hygiene and Tropical Medecine and Emeritus Professor at the University of Newcastle upon Tyne.
• Pr Mike RICHARDS, National Cancer Director, Department of Health.
• Pr David J. WEBB, Chairman of theAdvisor Board Scottish Medecines Consortium (SMC), Vice-President of the Royal College of Physisinas of Edinburg, Honorary President of the European Association for Clinical Pharmacology and Therapeutics.
Winners
- 2010
-
- Rivaroxaban (Xarelto, Bayer Schering Pharma)
- Acetat icatibant (Firazyr, Shire Pharmaceuticals)
- 2008
-
- Cervarix (GlaxoSmithKline)
- Gardasil (Sanofi Pasteur MSD)
- Déférasirox (Exjade, Novartis)
- 2006
-
- Omalizumab (Xolair, Novartis Pharma)
- Rotarix (GlaxoSmithKline)
- Alglucosidase alpha (Myozyne, Genzyme)
- 2004
-
- Polyoside pneumococcique (Prevenar, Wyeth)
- Enfuvirtide (Fuzéon, Produits Roche)
- 2002
-
- Imatinib (Glivec, Novartis)
- Trastuzumab (Herceptin, Roche)
- 2000
-
- Sildénafil (Viagra, Pfizer)
- Vaccin antiméningococcique (Meningitec, Wyeth)
- 1998
-
- Montelukast (Singulair, Merck-Sharp Dohme)
- Institut de technologie de Cambridge (mise au point d'anticorps monoclonaux pour la cicatrisation de la cornée)
- 1997
-
- Olanzapine (Zyprexa, Eli Lilly)
- 1996
-
- Aciclovir (Zovirax, GlaxoWellcome)
- 1995
-
- Saquinavir (Invirase, Roche)
- Lamictal (Lamotrigine, GlaxoWellcome)
- 1994
-
- Cimétidine (Tagamet, SmithKline)
- 1993
-
- Vaccin antihépatite A (Havrix, SmithKline Beecham)
- 1992
-
- Finastéride (Proscar, MSD)
- Surfactant (Exosurf, Wellcome)
- 1991
-
- Filgrastim (Neupogen, Roche/Amgen)
- Sandostatine (Somatostatine, Sandoz)
- Simvastatine (Zocor, Merck-Sharp Dohme)
- 1990
-
- Érythropoïétine (Eprex, Cilag)
- Ondansétron (Zofran, Glaxo)



